Feig.Manual MD Anderson_7ed

157

Capítulo 6 / Sarcoma de tejidos blandos y huesos

Keung EZ, Rajkot N, Torres KE, et al. Evaluating the impact of surveillance follow-up intervals in patients following resection of primary well-differentiated liposarcoma of the retroperitoneum. Ann Surg Oncol . 2021;28(1):570–575. Lansu J, Bovée JVMG, Braam P, et al. Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonran domized controlled trial. JAMA Oncol . 2021;7(1):e205865. Le Cesne A, Ouali M, Leahy MG, et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol . 2014;25:2425–2432. Livingston JA, Bugano D, Barbo A, et al. Role of chemotherapy in dedifferentiated liposarcoma of the retroperito neum: defining the benefit and challenges of the standard. Sci Rep . 2017;7(1):11836. Martin-Broto J, Hindi N, Lopez-Pousa A, et al. Assessment of safety and efficacy of combined trabectedin and low dose radiotherapy for patients with metastatic soft-tissue sarcomas: a nonrandomized phase 1/2 clinical trial. JAMA Oncol . 2020;6(4):535–541. Nassbaum DP, Rushing CN, Lane WO, et al. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. Lancet Oncol . 2016;17:966–975. Raut CP, Espat NJ, Maki RG, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate-or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol . 2018;4(12):e184060–e184060. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft tissue sarcomas of the extremities: prospective ran domized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg . 1982;196:305–315. Salerno KE, Alektiar KM, Baldini EH, et al. Radiation therapy for treatment of soft tissue sarcoma in adults: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol . 2021;11(5):339–351. Smith MJF, Ridgway PF, Catton CN, et al. Combined management of retroperitoneal sarcoma with dose intensifi cation radiotherapy and resection: long-term results of a prospective trial. Radiother Oncol . 2014;110:165–171. Stucky CCH, Wasif N, Ashman JB, Pockaj BA, Gunderson LL, Gray RJ. Excellent local control with preoperative radiation therapy, surgical resection, and intra-operative electron radiation therapy for retroperitoneal sarcoma. J Surg Oncol . 2014;109:798–803. Tan MCB, Brennan MF, Kuk D, et al. Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma. Ann Surg . 2016;263:593–600. Woll PJ, Reichardt P, Le Cesne A, et al. EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenogras tim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol . 2012;13:1045–1054.

Copyright © 2024 Wolters Kluwer, Inc. Unauthorized reproduction of the content is prohibited.